Cargando…

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA

Infection with human immunodeficiency virus 1 (HIV-1) remains incurable because long-lived, latently-infected cells persist during prolonged antiretroviral therapy. Attempts to pharmacologically reactivate and purge the latent reservoir with latency reactivating agents (LRAs) such as protein kinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Jared P., Armitage, Lucas H., Aldridge, Daniel L., Cash, Melanie N., Wallet, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Company of Biologists Ltd 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774897/ https://www.ncbi.nlm.nih.gov/pubmed/33234703 http://dx.doi.org/10.1242/bio.052969

Ejemplares similares

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui
por: Wang, Pengfei, et al.
Publicado: (2017)

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
por: Darcis, Gilles, et al.
Publicado: (2015)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells
por: Copertino, Dennis C., et al.
Publicado: (2023)

CRISPR/Cas9 knockout of USP18 enhances type I IFN responsiveness and restricts HIV‐1 infection in macrophages
por: Taylor, Jared P., et al.
Publicado: (2018)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

RasGRPs Are Targets of the Anti-Cancer Agent Ingenol-3-Angelate
por: Song, Xiaohua, et al.
Publicado: (2013)

Ingenol Protects Human T Cells From HIV-1 Infection
por: Hong, Kee-Jong, et al.
Publicado: (2011)

Ingenol mebutate treatment in keloids
por: De Felice, Bruna, et al.
Publicado: (2015)

Tattoo removal with ingenol mebutate
por: Cozzi, Sarah-Jane, et al.
Publicado: (2017)

Synthesis and mechanisms of action of novel harmine derivatives as potential antitumor agents
por: Zhang, Xiao-Fei, et al.
Publicado: (2016)

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
por: Garrido, Carolina, et al.
Publicado: (2016)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling
por: Li, Shifei, et al.
Publicado: (2023)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023)

Opioid use does not limit potent low-dose HIV-1 latency reversal agent boosting
por: Lilie, Tyler, et al.
Publicado: (2023)

Tracking HIV Rebound following Latency Reversal Using Barcoded HIV
por: Marsden, Matthew D., et al.
Publicado: (2020)

Latency Reversing Agents: Kick and Kill of HTLV-1?
por: Schnell, Annika P., et al.
Publicado: (2021)

Impact of latency‐reversing agents on human macrophage physiology
por: Hany, Laurent, et al.
Publicado: (2022)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure
por: Clutton, Genevieve Tyndale, et al.
Publicado: (2018)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products
por: Richard, Khumoekae, et al.
Publicado: (2018)

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
por: Vignesh, Ramachandran, et al.
Publicado: (2017)

Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment
por: Relaño-Rodríguez, Ignacio, et al.
Publicado: (2019)

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
por: Ait-Ammar, Amina, et al.
Publicado: (2020)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
por: Bricker, Katherine M., et al.
Publicado: (2021)

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen
por: Liu, Hongbing, et al.
Publicado: (2021)

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
por: Salahong, Thanarat, et al.
Publicado: (2021)

Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents
por: Vollbrecht, Thomas, et al.
Publicado: (2020)

Anti-latency agents to purge HIV reservoirs
por: Moreno, Santiago
Publicado: (2012)

Professor Kshitish Chandra Saha
por: Coondoo, Arijit
Publicado: (2016)

First person – Santu Saha
Publicado: (2023)

Synthesis and Biological Evaluation of Harmirins, Novel Harmine–Coumarin Hybrids as Potential Anticancer Agents
por: Pavić, Kristina, et al.
Publicado: (2021)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9m9smcd2efergfq9qkl6kk9d00